Data Resource Profile:The Danish National Prescription Registry by Pottegård, Anton et al.
Syddansk Universitet
Data Resource Profile
Pottegård, A; Schmidt, Sigrún Alba Johannesdottir; Kildemoes, Helle Wallach; Sørensen,
Henrik Toft; Hallas, Jesper; Schmidt, Morten
Published in:
International journal of epidemiology
DOI:
10.1093/ije/dyw213
Publication date:
2017
Document version
Peer reviewed version
Document license
CC BY-NC
Citation for pulished version (APA):
Pottegård, A., Schmidt, S. A. J., Kildemoes, H. W., Sørensen, H. T., Hallas, J., & Schmidt, M. (2017). Data
Resource Profile: The Danish National Prescription Registry. International journal of epidemiology. DOI:
10.1093/ije/dyw213
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. aug.. 2017
Data Resource Profile
Data Resource Profile: The Danish National
Prescription Registry
Anton Pottega˚rd,1* Sigrun Alba Johannesdottir Schmidt,2
Helle Wallach-Kildemoes,3 Henrik Toft Sørensen,2 Jesper Hallas1 and
Morten Schmidt2,4
1Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark,
2Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 3Social and
Clinical Pharmacy, University of Copenhagen, Copenhagen, Denmark and 4Department of Internal
Medicine, Regional Hospital of Randers, Randers, Denmark
*Corresponding author. Clinical Pharmacology and Pharmacy, University of Southern Denmark, JB Winsløwsvej 19, 2
5000 Odense C, Denmark. E-mail: apottegaard@health.sdu.dk
Accepted 5 July 2016
Data resource basics
Nationwide Danish data for research
Denmark has a long tradition of creating nationwide ad-
ministrative and health registries.1,2 Examples include its
registries on causes of death,3 hospitalizations4 and can-
cer,5 and on socioeconomic parameters such as income6
and education.7 A registry central to Danish pharmacoepi-
demiology is the Register of Medicinal Product Statistics,
established in 1994. This registry includes data on all drugs
sold in primary care or purchased for use in Danish hos-
pitals. Whereas aggregate data on gross sales of drugs are
freely available online [www.medstat.dk],8 individual-level
data on prescriptions filled by Danish residents at com-
munity pharmacies are available as an independent sub-
registry—the National Prescription Registry (NPR).9 NPR
data have been available to researchers through Statistics
Denmark since 2003, and more recently also through the
Danish Health Data Authority. Given these recent changes
in data access and the need to evaluate the Registry’s
strengths and limitations, this data resource profile pro-
vides a review of the NPR, with emphasis on its role in
research.
Prescription drugs in the Danish healthcare
system
The Danish National Health Service10 provides universal
tax-supported healthcare, guaranteeing all Danish resi-
dents free access to general practitioners (GPs) and hos-
pitals. GPs are the cornerstone of the Danish healthcare
system, providing health care free at the point of delivery
and acting as gatekeepers for specialist care. GPs often re-
sume the responsibility for treatment after a diagnosis has
been established by a specialist. Therefore, GPs issue \most
prescriptions in Denmark.11
Patient co-payments are required for prescription drugs.
A central authority (the Reimbursement Committee) de-
cides whether a particular medicine is reimbursable, and
all reimbursable medicines are covered by a tax-financed
drug reimbursement scheme. According to this scheme, the
percentage of reimbursed costs increases with an individ-
ual’s total expenditures for reimbursable medicines during
the most recent 365 days.12 At present, the first 130e is
paid in full by the patient (except for children, who imme-
diately receive a 60% reimbursement). Then, reimburse-
ments cover increasing percentages of costs, in steps of
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50%, 75% and 85%, until out-of-pocket expenditures are
capped at about 500e.13 All residents are automatically
covered by the reimbursement scheme.
The Danish community pharmacy sector consists of
314 large pharmacies, on average covering about 17 000
residents and serving about 600 customers per day.
Pharmacies are privately operated, but subject to state
regulation. The Danish Ministry of Health and the Danish
Medicines Agency control the sector through a licensing
system, which determines the number of pharmacies and
their location. Although patients are not obliged to use a
single pharmacy, they generally are loyal to their preferred
pharmacy.11
Prescription drugs are mainly dispensed in their original
packs. No upper limit exists for the amount of drug that
can be dispensed at any one time. However, when medical
treatment is stable, patients typically receive a 3-month
supply (corresponding to packages of 100 tablets for drugs
used once daily).14 About 62 000 Danish residents, mostly
elderly, receive their drugs as dose-dispensed medications
with a 14-day supply period.15
Data collected
Coverage
Since 1995, the NPR has recorded detailed information on
prescriptions redeemed in Denmark. Drugs prescribed to
nursing-home residents are also included. Prescriptions for
children were issued under the name of the mother until 1996,
and then under the child’s name. There are three notable in-
stances when drugs are not filled at community pharmacies
and thus are not captured by the registry: (i) drugs used during
hospital admissions; (ii) drugs used by certain institutionalized
individuals (typically due to psychiatric illnesses); and (iii)
drugs supplied directly by hospitals or treatment centres (e.g.
chemotherapeutic agents, immunosuppressant drugs and
methadone for substance abusers).
Contents
The NPR receives data recorded in the electronic dispens-
ing systems of community pharmacies. The Registry con-
tains 46 variables that characterize each redeemed
prescription, including those describing the patient, the
drug dispensed, the health provider issuing the prescription
and the dispensing pharmacy. An overview of the main
variables is provided in Table 1. Complete documentation
is provided in Danish by Statistics Denmark16 and by the
Danish Health Data Authority.17
The core variables are the Civil Personal Register (CPR)
number (a unique personal identifier used in all Danish
registries), the dispensing date (i.e. date the prescription
was redeemed) and the Nordic article number (a unique
six-digit code designating each drug package). This num-
ber encodes several other variables, including package size,
strength, form and Anatomical Therapeutic Chemical
(ATC) code. The ATC system, a hierarchical classification
system developed by the World Health Organization
(WHO), is described in full elsewhere18 and is searchable
at [http://www.whocc.no/atc_ddd_index/]. The total
amount of drug purchased can be calculated by combining
data on package size, strength and number of dispensed
Table 1. Key variables included in the Danish National Prescription Registry
Variable description Variable name Explanation
Patient details
Personal identifier CPR Civil Personal Register (CPR) number, which encodes date of birth and
gender and enables unambiguous linkage to other Danish registries
Dispensing details
Date EKSD Date of completed sale/debit/dispensing
Packages APK Number of packets/units of the product dispensed
Product code VNR Product code of the product dispensed
Name* PNAME Product name
ATC* ATC WHO-defined Anatomical Therapeutical Chemical code
DDD* VOLUME Number of defined daily doses per package
Amount* PACKSIZE Number of tablets/units per package
Strength* STRNUM Numerical strength per tablet/unit
Form* DOSFORM Formulation of the drug
Other
Prescriber RECU Identifier for the prescriber, e.g. a hospital or a general practice unit
Pharmacy IBNR Identifier for the dispensing pharmacy
*Within Statistics Denmark, these variables are included directly in the registry, whereas at the Danish Health Data Authorities they are obtained via linkage
with the product code.
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packages. As an alternative, the number of defined daily
doses (DDDs) is also recorded in the NPR.18
Data quality
Data in the NPR are considered both complete and valid as
from 1995. Although data were also collected in 1994,
they are not considered of sufficient quality to be used for
research purposes and are therefore not made available to
researchers. Use of bar codes throughout the dispensing
process at Danish pharmacies minimizes the risk of data
entry errors. As well, pharmacies receive a financial incen-
tive for complete registration of all purchases through the
reimbursement scheme.
Only two studies, performed in the mid-1990s, have
directly validated the content of the NPR.19,20 Each exam-
ined a specific therapeutic group (oral anticoagulants19
and strong analgesics20) and reported a high degree of
completeness of registration. These studies were based on
the regional Aarhus University Prescription Database
(AUPD)21 (see below), whose data are identical to those
also included in the NPR. An indirect validation has also
been performed, comparing data in the NPR with women’s
self-reported drug use during pregnancy,22 and a high de-
gree of concordance was found.
The validity of recorded prescriber information has pre-
viously been questioned, because pharmacy staff manually
enter prescriber information from non-electronic prescrip-
tions. However, a recent study found that the validity of
classification into prescriber type (GPs, hospital physicians
and physicians in private practice) was generally high for
non-electronic prescriptions.23 Since the proportion of
non-electronic prescriptions is declining and the variable is
considered valid for electronic prescriptions, prescriber in-
formation in the NPR may be considered valid overall (at
least in recent years). Still, the sensitivity towards prescrip-
tions issued by private-practising specialists remains a
concern.23
Data resource use
NPR data have been used extensively in pharmacoepide-
miological research.24 Thus, the registry has been used as a
stand-alone resource for basic drug utilization studies,25
and also in studies of treatment quality.26 The full poten-
tial of the NPR is enabled through linkage to other regis-
tries, e.g. the Danish National Patient Registry,4 allowing
population-based drug outcome studies. Flawless linkage is
achieved using the CPR number assigned to all Danish resi-
dents since 1968.2 This has been employed in studies of
acute drug effects, with outcomes such as risk of haemor-
rhage.27 Also, collection of data in the NPR for more than
20 years allows for studies of long-term exposure or dis-
eases with a long latent period, such as associations be-
tween prescription drug use and cancer.28 Prescriptions
recorded in the NPR also have been used as disease prox-
ies, particularly when diseases cannot be identified with
sufficient sensitivity based solely on hospital-based diag-
noses. Examples include using drugs to treat alcohol abuse
to identify alcoholics,29 using antibiotics to identify acute
infections30 and using antidiabetic drugs to identify pa-
tients with diabetes.31
Strengths and weaknesses
Weaknesses
The NPR’s major limitation is lack of data on indication
for use, intended duration and dosage. This problem is fur-
ther complicated by ‘original pack dispensing’, i.e. drugs
are supplied for a period of time that is in principle un-
known. Thus, researchers need to make transparent and
educated assumptions regarding treatment duration, based
on treatment guidelines, pill strength, package size and
number of packages. This is particularly important in stud-
ies mapping person-time of exposure to a given drug.
Examples are studies of NSAID-associated risks of myocar-
dial infarction32 and studies of drug use during preg-
nancy.33 Necessary assumptions can be made using the
waiting time distribution34 or specific clinical input, e.g.
assuming an intake of one tablet a day for statin35 or anti-
platelet treatment.27 Regardless of the basis for such as-
sumptions, it is necessary to consider deviations caused by
irregular prescription refills (e.g. stockpiling) or non-
adherence. This issue is of particular concern in studies of
drugs used on an ‘as needed’ or irregular basis (e.g. non-
aspirin NSAIDs34) and in studies using designs that rely
heavily on the exact timing of drug intake (e.g. use of self-
controlled designs in studying acute drug effects36).
Another limitation of the NPR is its lack of data on
over-the-counter (OTC) drugs. However, this limitation
does not preclude analyses of drugs that can be obtained
both with and without prescriptions. First, it is possible to
estimate the extent of OTC use through the online data-
source [Medstat.dk].8 Second, OTC use is often unequally
distributed in the population, as persons with frequent use
of reimburseable medications (e.g. elderly individuals)
have a financial incentive to obtain them by prescription.
A study that quantified the potential of the NPR to capture
individual-level aspirin and non-aspirin NSAID use37
found that its ability to identify NSAID use was high. It
also found that unless the relative risk measure was very
high, misclassification due to OTC use (even at a magni-
tude similar to that of NSAIDs) had little impact on the
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relative risk estimate, rate difference or aetiological frac-
tion associated with the drug.37.
Left truncation or censoring due to lack of data before
1995 is also a concern in some studies. While the time
frame of the NPR is superior to many other similar regis-
tries,24 it still may be too short to correctly identify the
time of treatment initiation or cumulative dose of a drug.
In some situations, the resulting potential misclassification
can be assessed by comparison with the regional prescrip-
tion registries, i.e. the Odense Pharmacoepidemiological
Database (OPED)38 or AUPD,21 which date back to 1989–
90 (see below).39
Strengths
The NPR provides more than 20 years of nationwide
coverage, which in the Nordic setting is paralleled only by
the Finnish prescription registry established in 1994.24
Another important strength is its national coverage. Other
data sources, such as those based on American health
maintenance organizations, may have coverage beyond 20
years, but most have large annual turnover in beneficia-
ries.40 In studies using the NPR, loss to follow-up is caused
only by emigration, which can be traced through the
Danish Civil Registration System.2
In contrast to other large databases, such as the UK
Clinical Practice Research Datalink (CPRD)41 and the
Health Improvement Network (THIN),42 the NPR is based
on redemption of prescriptions rather than on issued pre-
scriptions. This provides an important advantage, as a
filled prescription is a better surrogate for actual drug in-
take than a written prescription. Thus, about one-tenth of
prescriptions issued in Danish general practices are not
subsequently filled (primary non-adherence).43 For pre-
scriptions that were filled, the date of dispensing was a
valid proxy for the date of issue, as most patients filled
their prescription within 2 days.43
Another important feature of the NPR is its inclusion of
drugs used by nursing-home residents, unlike the otherwise
similar Finnish and Norwegian prescription registries.44,45
This feature limits differential misclassification of exposure
status due to frailty among elderly individuals and per-
mits investigation of drug consumption among the very
elderly.
Comparison with other sources of prescription
data
The NPR is compared with other Danish and Nordic pre-
scription registries24 in Table 2. Denmark has three other
prescription registries: two regional registries (OPED38
and AUPD21) and one nationwide registry (Danish T
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National Health Service Database, DNHSD).46 The OPED
has covered the Region of Funen (600 000 inhabitants)
since 1990 and the Region of Southern Denmark
(1 200 000 inhabitants) since 2007. The AUPD has covered
the former North Jutland county since 1989 and most of
the Central and Northern Denmark Regions (1 800 000 in-
habitants) since 1998. The DNHSD has nationwide cover-
age since 2004, and has to a large extent replaced the use
of AUPD.46 Importantly, these three additional prescrip-
tion registries cover only reimbursed prescription drugs,
precluding analysis of such agents as benzodiazepines, oral
contraceptives and certain antibiotics. However, in con-
trast to the NPR, they can provide data in a non-
anonymized form to researchers when necessary approvals
are obtained. This is particularly useful in intervention
studies involving certain drugs, in validation studies and in
other studies where additional information, for instance
from medical charts, is essential.
Data resource access
Data access
Since 2003, the NPR has been available to researchers
through an anonymized duplicate copy stored on servers
within Statistics Denmark. As well, it has been possible to
access the NPR on servers within the Danish Health Data
Authority since 2014. The servers hosted by the Research
Service at Statistics Denmark have been described previ-
ously,47 and the set-up at the Danish Health Data
Authority is very similar. The two institutions offer a ser-
ver environment where researchers can gain access to data
for well-defined research projects. Data are accessed
through a double log-on procedure and all data are pro-
vided in anonymized form. The servers contain conven-
tional analytical packages, such as STATA, SAS, R and
SPSS. Importantly, the NPR data are only available in ano-
nymized form and cannot be accessed outside the Statistics
Denmark and Danish Health Authority platforms. Thus,
data from the NPR cannot be transferred to an outside re-
searcher or any other institution. Within Statistics
Denmark and the Danish Health Data Authority, data can
be linked to other registries or other types of individual-
level information (e.g. surveys) using the 10-digit personal
identifier previously described.2
The most important differences between the platforms
at Statistics Denmark and the Danish Health Data
Authority pertains to data recency and linkage to socioeco-
nomic registries (Table 3). As socioeconomic data, such as
income6 and education,7 are kept within Statistics
Denmark, they cannot be utilized in studies using the ser-
vers at the Danish Health Data Authority. Regarding data
recency, the Danish Health Data Authority server is con-
sidered superior. Most health registry data stored on this
server, including NPR data, are made available to re-
searchers with as little as a 1-2 month delay. This facili-
tates studies of early uptake of recently marketed drugs48
and allows researchers to address ongoing public health
concerns in a timely manner.49 In contrast, the duplicate
copy of the NPR within Statistics Denmark is usually
updated only twice annually, resulting in a delay of up to 9
months. Access to the two platforms, and thus to the NPR,
is granted by application to their respective boards. A for-
mal affiliation or collaboration with a Danish research in-
stitution is required.47
Approvals and legislation
In addition to legislation covering all Danish health regis-
tries, the NPR is governed by the Pharmacy Sector Act.50
This law imposes special restrictions on use of the NPR, to
ensure the anonymity of individuals beyond the anonym-
ization of any direct personal identifiers. In practice, ano-
nymization is often achieved by removing or granulating
any data that could be used to indirectly identify single in-
dividuals, e.g. by replacing exact birthdate with birth
month and municipality of residence with region of resi-
dence. The research services at Statistics Denmark and the
Danish Health Data Authority guide and facilitate this pro-
cess. Upcoming legislative changes, expected to take effect
early 2017, will likely lift these restrictions.
A formal approval regarding data protection is not al-
ways needed, since the Danish Data Protection Agency has
given overall approval to both Statistics Denmark and the
Research Services at the Danish Health Data Authority
Table 3. Comparison of the platforms used for data access to
the Danish National Prescription Registry at Statistics
Denmark and the Danish Health Data Authority
Statistics
Denmark
Danish Health
Data Authority
Year prescription
data became available
1995 1995
Linkable to other
health registries
Yes Yes
Linkable to socioeconomic
registries
Yes No
Permissible for researchers
to add his/her own data
Yes Yes
Non-anonymized
data available
No No
Recency of data Up to 9
months old
Up to 2
months old
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because of their high-security systems. As such, projects
based solely on data from either agency and confined to
their servers are indirectly approved by the Data Protection
Agency once the projects receive agency approval from ei-
ther Statistics Denmark or the Danish Health Data
Authority. If researchers add external data to the project, a
data protection approval becomes necessary. Approval by
an ethics review board is not required in studies involving
the NPR, as projects based solely on registry data are ex-
empt from ethical approval according to Danish law.47
Furthermore, the NPR cannot be accessed for studies
requiring a non-anonymized version, where such approval
is typically required.
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Profile in a nutshell
• The NPR was established to monitor drug use in
Denmark for administrative purposes.
• The NPR contains individual-level data on all prescrip-
tions filled at Danish community pharmacies since
1995, and these data are linkable to all other Danish
registries using the Civil Personal Register number.
• Data are registered using electronic dispensing sys-
tems at Danish pharmacies and therefore considered
accurate and complete.
• The NPR includes 46 variables describing the pa-
tient, the drug dispensed (including prescription fill-
ing date, drug composition and amount of drug), the
health provider issuing the prescription and the dis-
pensing pharmacy. No valid data are obtained on in-
dication for use, prescribed daily dose or intended
duration of use.
• The NPR can be accessed in anonymized form via
servers at Statistics Denmark and the Danish Health
Data Authority. Data cannot be transferred outside
these servers.
6 International Journal of Epidemiology, 2015, Vol. 0, No. 0
23. Rasmussen L, Valentin J, Gesser K et al. Validity of the
Prescriber Information in the Danish National Prescription
Registry. Basic Clin Pharmacol Toxicol 2016; Apr 21. doi:
10.1111/bcpt.12610. [Epub ahead of print.]
24. Wettermark B, Zo€ega H, Furu K et al. The Nordic prescription
databases as a resource for pharmacoepidemiological research - a
literature review. Pharmacoepidemiol Drug Saf 2013;22:691–99.
25. Pottega˚rd A, Broe A, Hallas J et al. Use of proton pump inhibi-
tors among adults: A Danish nationwide drug utilization study.
Ther Adv Gastroenterol 2016; (in press).
26. Davidsen JR, Søndergaard J, Hallas J et al. Increased use of
inhaled corticosteroids among young Danish adult asthmatics:
an observational study. Respir Med 2010;104:1817–24.
27. Pottega˚rd A, Garcıa Rodrıguez LA, Poulsen FR et al.
Antithrombotic drugs and subarachnoid haemorrhage risk. A
nationwide case-control study in Denmark. Thromb Haemost
2015;114:1064–75.
28. Pottega˚rd A, Friis S, dePont Christensen R et al. Identification of
associations between prescribed medications and cancer: a na-
tionwide screening study. EBioMed 2016;7:73–79.
29. Askgaard G, Friis S, Hallas J et al. Use of disulfiram and risk of
cancer: a population-based case-control study. Eur J Cancer
Prev 2014;23:225–32.
30. Schmidt M, Horvath-Puho E, Thomsen RW et al. Acute infections
and venous thromboembolism. J InternMed 2012;271:608–18.
31. Carstensen B, Kristensen JK, Marcussen MM et al. The National
Diabetes Register. Scand J Public Health 2011;39:58–61.
32. Fosbøl EL, Gislason GH, Jacobsen S et al. Risk of myocardial in-
farction and death associated with the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) among healthy individuals: a na-
tionwide cohort study. Clin Pharmacol Ther 2009;85:190–97.
33. Pottega˚rd A, Hallas J, Andersen JT et al. First-trimester exposure
to methylphenidate: a population-based cohort study. J Clin
Psychiatry 2014;75:e88–93.
34. Pottega˚rd A, Hallas J. Assigning exposure duration to single pre-
scriptions by use of the waiting time distribution.
Pharmacoepidemiol Drug Saf 2013;22:803–09.
35. Wallach-Kildemoes H, Andersen M, Diderichsen F, et al.
Adherence to preventive statin therapy according to socioeco-
nomic position. Eur J Clin Pharmacol 2013;69:1553–63.
36. Hallas J, Pottega˚rd A. Use of self-controlled designs in pharma-
coepidemiology. J Intern Med 2014;275:581–89.
37. Schmidt M, Hallas J, Friis S. Potential of prescription registries
to capture individual-level use of aspirin and other nonsteroidal
anti-inflammatory drugs in Denmark: trends in utilization 1999–
2012. Clin Epidemiol 2014;6:155–68.
38. Gaist D, Sørensen HT, Hallas J. The Danish prescription regis-
tries. DanMed Bull 1997;44:445–48.
39. Pottega˚rd A, Hallas J, Jensen BL et al. Long-term lithium use and
risk of renal and upper urinary tract cancers. J Am Soc Nephrol
2016;27:249–55.
40. Schneeweiss S, Avorn J. A review of uses of health care utiliza-
tion databases for epidemiologic research on therapeutics. J Clin
Epidemiol 2005;58:323–37.
41. Herrett E, Gallagher AM, Bhaskaran K et al. Data Resource
Profile: Clinical Practice Research Datalink (CPRD). Int J
Epidemiol 2015;44:827–36.
42. Lewis JD, Schinnar R, Bilker WB et al. Validation studies of the
health improvement network (THIN) database for pharmacoepi-
demiology research. Pharmacoepidemiol Drug Saf 2007;16:
393–401.
43. Pottega˚rd A, dePont Christensen R, Houji A et al. Primary non-
adherence in general practice: a Danish register study. Eur J Clin
Pharmacol 2014;70:757–63.
44. Klaukka T. The Finnish database on drug utilization. Norw J
Epidemiol 2001;11:19–22.
45. Furu K. Establishment of the nationwide Norwegian
Prescription Database (NorPD)—new opportunities for research
in pharmacoepidemiology in Norway. Nor Epidemiol
2008;18:129–36.
46. Johannesdottir SA, Horvath-Puho E, Ehrenstein V, et al.
Existing data sources for clinical epidemiology: The Danish
National Database of Reimbursed Prescriptions. Clin Epidemiol
2012;4:303–13.
47. Thygesen LC, Daasnes C, Thaulow I et al. Introduction to
Danish (nationwide) registers on health and social issues: struc-
ture, access, legislation, and archiving. Scand J Public Health
2011;39:12–16.
48. Sørensen R, Gislason G, Torp-Pedersen C et al. Dabigatran use
in Danish atrial fibrillation patients in 2011: a nationwide study.
BMJOpen 2013;3. doi:10.1136/bmjopen-2013-002758.
49. Hellfritzsch M, Rathe J, Stage TB et al. Generic switching of war-
farin and risk of excessive anticoagulation: a Danish nationwide
cohort study. Pharmacoepidemiol Drug Saf 2016;25:336–43.
50. Ministry of Health. [Law on Pharmacy Activities.] (In Danish.)
Document dated, 3 September 2014. https://www.retsinforma
tion.dk/forms/r0710.aspx?id¼164756&exp¼1 (14 September,
date last accessed).
International Journal of Epidemiology, 2015, Vol. 0, No. 0 7
